Skip to content

ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

 
  • EnEn
  • SvSv
  • About us
    • Management
    • Board of Directors
  • Therapeutic areas
    • Liver metastases
    • Gastric Cancer
  • Pipeline
    • Orviglance® (Mangoral)
    • Oncoral
  • Partnering
  • IR & Media
    • Press releases
    • Financial Reports
    • Presentations & articles
    • Share
    • Shareholders
    • Insiders
    • Equity research
    • Financial calendar
    • Events
    • IR Contact
    • Prospectuses
    • CMD 2020
    • Subscribe to press releases
  • Governance
    • General Meeting
    • Articles of Association
    • Nomination Committee
    • Board of Directors
    • Audit Committee
    • Remuneration Committee
    • Commercialization Committee
    • Remuneration
    • Auditors
    • Internal control
  • Career
    • Open positions
    • Our values
    • Meet us
  • Contact
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
Subscribe to press releases
All All press releasesRegulatory press releasesFinancial reports
Regulatory
2022-11-04 | QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2022-08-18 | Half-year report 2022: Strong results from Orviglance Food Effect Study
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2022-05-11 | Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2022-04-11 | Ascelia Pharma publishes Annual Report for 2021
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2022-02-10 | Quarterly Report Q4 2021: Strong data for Orviglance vs. a gadolinium contrast agent
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2021-11-04 | Quarterly Report Q3 2021: Oncoral – entering clinical collaboration
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2021-08-19 | Quarterly Report Q2 2021: Preparing Oncoral for the next level
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2021-05-12 | Quarterly Report Q1 2021: US office opened in preparation of launch
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2021-03-30 | Ascelia Pharma publishes Annual Report for 2020
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2021-02-16 | Quarterly Report Q4 2020: Mangoral shows high diagnostic value in new study
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2020-11-05 | Quarterly Report Q3-2020: Raised market estimate for Mangoral and preparing for market launch
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2020-08-20 | Quarterly Report Q2-2020: First participant in the hepatic study
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2020-05-13 | Interim Financial Report Q1-2020: First patient enrolled in Phase 3 study SPARKLE
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2020-04-06 | Ascelia Pharma publishes Annual Report for the financial year 2019
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2020-02-14 | 2019 year-end financial report: Sites opened for recruitment to the pivotal Phase III study SPARKLE
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2019-10-14 | Ascelia Pharma publishes Annual Report for the financial year 2018/2019
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2019-08-22 | Phase III study of Mangoral to start in H2-2019
PDF
Report
Financial Data
Presentation
Webcast
Learn more

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. […]
Learn more

Meet us

Ascelia’s employees are passionate and driven to develop products that will help people with rare cancer conditions live longer and healthier lives.
Learn more

Our values

Our values inspire our ambitions, decision making and collaboration to help us reach our highest potential. INTEGRITY We build powerful relationship with mutual respect and adhere to the high ethical […]
  1. Start

About us

  • Start
  • About us
  • Career
  • Contact
  • Privacy policy
  • About cookies
  • Cookie settings

Pipeline

  • Oncoral
  • Orviglance®

IR & Media

  • Subscribe to press releases
  • Press releases & News
  • Financial Reports

Contact us

Ascelia Pharma AB
Hyllie Boulevard 34
215 32 Malmö
Sweden
Phone: +46 735 17 91 18

info@ascelia.com

Follow us

 

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development.

Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

© Copyright 2021 - Ascelia Pharma AB | We use cookies to improve our services | Disclaimer Market data could be delayed. Delivered by Modular Finance.

Video
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all